key: cord-0894940-20zf03y3
authors: Alzaid, Fawaz; Julla, Jean‐Baptiste; Diedisheim, Marc; Potier, Charline; Potier, Louis; Velho, Gilberto; Gaborit, Bénédicte; Manivet, Philippe; Germain, Stéphane; Vidal‐Trecan, Tiphaine; Roussel, Ronan; Riveline, Jean‐Pierre; Dalmas, Elise; Venteclef, Nicolas; Gautier, Jean‐François
title: Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID‐19 in type 2 diabetes
date: 2020-08-20
journal: EMBO Mol Med
DOI: 10.15252/emmm.202013038
sha: 6963a9316bbef678c5e3c400de3b59e69584f90c
doc_id: 894940
cord_uid: 20zf03y3

Early in the COVID‐19 pandemic, type 2 diabetes (T2D) was marked as a risk‐factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at‐risk groups based on immuno‐inflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated with COVID‐19 severity in T2D. Broad‐spectrum immunophenotyping quantified 15 leukocyte populations in peripheral circulation from a cohort of 45 hospitalised COVID‐19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxic CD8(+) lymphocytes was associated with severe COVID‐19 and requirement for intensive care in both non‐diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classical CD14(Hi) CD16(‐) monocytes were specifically associated with severe COVID‐19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type‐1 interferon pathway (IL6, IL8, CCL2, INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity of COVID‐19 in T2D. These findings allow precise identification of T2D patients with severe COVID‐19 as well as provide evidence that the type‐1 interferon pathway may be an actionable therapeutic target for future studies.

Coronavirus , an infectious disease caused by the severe acute respiratory syndrome coronavirus (SARS-CoV)-2, was first identified in Wuhan, China, in December 2019. SARS-CoV-2 induces strong systemic inflammation and acute injury of the lung and potentially other organs (Merad & Martin, 2020) . As of June 30 th 2020, over 10 million cases have been reported worldwide, with an estimated mortality of 5-6% (Dong et al, 2020) . Early reports stated that individuals with diabetes are at high risk of complications or death from severe COVID-19 (Zhu et al, 2020) . Later studies indicated that factors such as age, obesity or hypertension, although commonly associated with diabetes, independently increase risk (Wu et al, 2020; . The complex aetiologies of these conditions and of type 2 diabetes (T2D) makes deciphering the mechanisms that increase severity of COVID-19 a complex task.

Recent reports have found important links between systemic metabolism, glucose homeostasis and responses to . Notably, studies have shown that glycaemic variability strongly influences outcome in COVID-19, where poorly-controlled blood glucose was associated with

This article is protected by copyright. All rights reserved markedly higher mortality compared to patients with well-controlled blood glucose (Zhu et al, 2020) . Similarly, high glycosylated haemoglobin (HbA1c), a proxy of glycaemic instability, has been associated with low oxygen saturation, inflammation and hypercoagulability in patients with COVID-19 (Wang et al, 2020b) . More recently, mechanistic studies have shown that the elevated glucose that sustains inflammatory metabolism in immune cells directly promotes viral replication and cytokine production in SARS-CoV-2 infection (Codo et al, 2020) .

Other potential immune-mediated mechanisms increasing severity of COVID-19 in patients with T2D, include: i) higher affinity cellular binding and efficient virus entry, ii) decreased viral clearance and iii) altered immune responses leading to hyperinflammation and aggravated cytokine storm syndrome.

Deregulation of the viral immune response in T2D is a plausible hypothesis. Lymphopenia has been consistently reported as one of the most frequent immune abnormalities in Chinese populations suffering severe COVID-19 (Tan et al, 2020) . Peripheral lymphocyte counts are low, with a higher proportion of pro-inflammatory Th17 CD4+ T cells, as well as elevated cytokine levels. In addition to altered T-cell dynamics, studies revealed altered monocyte phenotypes in severe forms of COVID-19 . The important implication of the innate immune system in COVID-19 aetiology is also evidenced by aberrant macrophage activation at the site of infection and in peripheral tissues (Park, 2020) .

Previous studies in T2D have highlighted abnormalities in monocyte phenotypic transition states related to disease severity and cardiovascular risk (Menart-Houtermans et al, 2014; Rogacev et al, 2012) . Interactions between the heightened immuno-inflammatory states in T2D and in COVID-19 cases may well be at the root of increased susceptibility of T2D patients to severe COVID-19. Deregulation of T-cell or monocyte frequency and function may result in unchecked innate and adaptive immune responses. Such responses lead to the uncontrolled and sustained inflammation observed in severe COVID-19 and at higher risk of mortality.

Herein, the immunophenotypic profile of diabetic and non-diabetic COVID-19 patients revealed specific phenotypic and morphological alteration of monocytes in T2D patients. Interestingly, the type-1 interferon sensitive transcription factor, the interferon regulatory factor (IRF)-5, is associated with altered monocyte fate in T2D. Finally, we provide evidence that a loss of CD8+ T-cells and classical monocytes concomitant to increased IRF5 expression dictate severity of COVID-19 in T2D patients.

This article is protected by copyright. All rights reserved

To characterise the influence of pre-existing diabetes in COVID-19 patients, we recruited a cohort of 45 COVID-19 patients from Lariboisière Hospital's University Centre for Diabetes and its Complications including 30 patients with T2D and 15 non-diabetic patients (ND). When comparing T2D with ND patients we have no differences in clinical or demographic criteria, with the exception of increased HbA1c and hypertension in T2D relative to ND (Table 1) .

HbA1c % was 4-fold higher and prevalence of hypertension was 1.3-fold higher in T2D with COVID-19 relative to ND patients with COVID-19.

To address our initial hypothesis of hyperinflammation and a dysregulated immune response to COVID-19 in patients with T2D we carried out broad-spectrum immunophenotyping of venous blood by multiparametric flow cytometry. Our approach quantifies 15 major innate and adaptive immune populations and subpopulations through lineage (CD45, CD3, HLA-DR, CD14, CD56 and CD20) and phenotypic markers (CD8, CD4, CD16, CD123, CD11c) in a single assay (Appendix Fig. S1A ). Upon quantification of major immune populations, we confirmed COVID-19 associated lymphopenia (<20 % CD45+ leukocytes) in both ND and T2D patients ( Fig. 1A and Appendix Fig. S1B ) (Melzer et al, 2015) . Unexpectedly, we found a 1.3fold decrease in CD14+ monocyte frequency in COVID-19 patients with T2D relative to ND patients ( Fig. 1A and Appendix Table S2 ). Of note, decreased monocyte frequency was not observed in T2D patients without COVID-19 (Appendix Fig. S1B and Appendix Table S3 ).

We did not find differences in lymphocyte, natural killer (NK), B-cell, granulocyte nor DC frequency between T2D and ND COVID-19 patients. Clinical laboratory full blood count (FBC) records corroborated these findings, with lymphopenia (< 1.5 x 10 9 /L or < 20% leukocyte count) in ND and T2D COVID-19 patients and a 1.5-fold decrease in monocyte counts in T2D relative to ND COVID-19 patients (Appendix Table S1 ).

We next quantified monocyte subtypes, to establish if a specific subtype is affected in T2D patients with COVID-19. Amongst CD14+ monocytes we found that a 1.4-fold decrease in classical monocyte (CD14-Hi, CD16-) frequency specifically accounted for the decrease in total monocytes in T2D relative to ND COVID-19 patients (Fig. 1B) . Of note, a similar trend of decreased (1.5-fold; p=0.07) classical monocyte frequency was also observed in T2D COVID-19 patients when compared to T2D patients without COVID-19 (Appendix Fig. S1C ).

We did not find any differences in the frequencies of lymphocytic, NK or DC subpopulations

This article is protected by copyright. All rights reserved between ND and T2D COVID-19 patients, whilst COVID-19-associated lymphopenia was represented across all lymphocyte subtypes in ND and T2D patients (Appendix Fig. S1C ).

Following these findings, we confirmed with principle component analyses (PCA) including variant immune population frequencies (lymphocyte and monocyte subpopulations), that three distinct clusters of patients emerged corresponding to ND COVID-19, T2D COVID-19 and T2D non-COVID-19 patients (Fig. 1C) . When the PCA was restricted to monocytic subpopulation frequencies, ND COVID-19 and T2D COVID-19 patients also show robust separation (Appendix Fig. S1D ). With multivariate ANOVA (MANOVA), integrating previously reported severe COVID-19 risk factors (gender, age, BMI, hypertension and diabetic status), we confirmed that lymphocyte and monocyte subpopulation variance is independently associated to patients with COVID-19 (p<0.01) and T2D (p<0.05). (Appendix Table S4 ).

To further characterise the monocyte pool, we quantified expression of monocyte activation markers CD16 and CD14, and of the functional pan-antigen presenting cell (APC) marker HLA-DR. We observed no difference in expression of CD16 nor HLA-DR between ND and T2D COVID-19 patients. However, T2D COVID-19 patients had 1.5-fold decreased expression of CD14 in their monocytes ( Fig. 2A and Appendix Fig. S2A ). These data indicate that monocytes, between both groups of patients, have retained a similar antigen presentation capacity (HLA-DR) and have transitioned away from classical activation (CD16) at the same rate. Monocytes from patients with COVID-19 and T2D have a pronounced loss of CD14, indicating an increased rate of commitment to non-classical activation.

Importantly, we observed a difference in monocyte size, as indicated by forward scatter (FSC) statistics, between T2D and ND patients with COVID-19. Monocyte size was significantly higher in T2D relative to ND patients with COVID-19 (1.4-fold increase; Fig. 2A ). This unexpected increase in cell size was specific to CD14+ monocytes, as we next compared FSC statistics in CD14 and CD3 bifurcate gates, and found no differences between T2D and ND COVID-19 patients in CD14-, CD3+ nor CD3-cells (Appendix Fig. S2B ). We next quantified the frequencies of the two distinct populations of FSC-Lo (conventional) and FSC-Hi (large) monocytes in our cohort and corroborated a 1.8-fold higher frequency of FSC-Hi monocytes in T2D relative to ND COVID-19 patients ( Fig. 2B and Appendix Fig. S2C ).

To characterise this atypical population of FSC-Hi monocytes, we quantified expression of

This article is protected by copyright. All rights reserved other known lineage markers (CD20, CD56, CD3) independently of patient status. We found no differences in the expression of non-monocyte markers (CD20, CD56, CD3) between FSC-Lo and FSC-Hi monocytes (Appendix Fig. S2D ). Monocyte activation and functional marker analyses revealed 1.9-fold increased expression of CD16 in FSC-Hi monocytes relative to We also investigated IL1B mRNA expression as a marker of inflammation linked to NLRP3 inflammasome activity. We found that although induced in COVID-19, IL1B expression was not different between ND and T2D patients (Appendix Fig. S2F ). Whereas other inflammatory markers related to the type-1 interferon signature were increased in COVID-19 and further increased with comorbid T2D (Appendix Fig. S2F ).

Given the above findings, we hypothesised that monocyte size would be of prognostic value at presentation. Thus, we stratified patients based on admission to intensive care unit (ICU) or care in general wards for non-critical patients (Gen). We found monocyte size to be increased by 1.6-fold in T2D patients admitted to the ICU relative to ND patients that did not require ICU admission (Fig. 2G ). When comparing ICU to Gen, disregarding diabetic status, we did not detect a statistically significant difference in monocyte size (Appendix Fig. S2G ).

This article is protected by copyright. All rights reserved

Given the described aetiology of COVID-19 and the patterns of inflammatory marker expression, we hypothesised that the type-1 Interferon response is engaged, and likely dysregulated in T2D patients. The transcriptional mediator of this pathway is the Interferon Regulatory Factor (IRF)-5, controlling expression of such genes as IL6 and IFNB1. It is highly expressed in the myeloid compartment, is canonically responsive to viral stimuli (Forbester et al, 2020; Weiss et al, 2015) , and is involved in regulating metabolic inflammation (Alzaid et al, 2016; Dalmas et al, 2015) .

We quantified mRNA expression of IRF5 and of its target type-1 interferon, IFNB1, in PBMCs from our cohort. We found IRF5 and IFNB1 to be induced in ND COVID-19 (respective 7.3and 1.8-fold increase relative to non-COVID-19 patients with T2D; Appendix To evaluate whether the inflammatory response mediated by IRF5 could infer protection or severity in COVID-19, we stratified our patients based on their admission to ICU. In the monocyte pool we observed a 2.1-fold increase in expression in patients admitted to ICU, significant only amongst ND COVID-19 patients (Fig. 3G) . Interestingly, in monocyte subpopula-

This article is protected by copyright. All rights reserved tions we observed a specific signature associated with ICU admission taking into account patient diabetic status. Classical monocyte expression of IRF5 is specifically increased by 2.1fold in patients admitted to the ICU, whereas intermediate monocyte expression of IRF5 is only increased in T2D patients admitted to ICU (respectively 3.3-and 1.7-fold relative to ND and T2D not requiring ICU admission; Fig. 3H ).

Despite the majority of ICU admissions from our cohort being patients with T2D; the proportions of ICU admissions within ND patients was comparable (26.7% of ND vs and 34.5% of T2D; Fig. 4A ). To decipher the immunophenotypic and inflammatory signatures more specifically associated with COVID-19 severity in T2D, we compared mild-moderate and severecritical cases of COVID-19 in this patient group.

When patients with T2D are stratified based on ICU admission, we observe a significant 1.6fold decrease in monocyte frequency and a trend to decreased lymphocyte frequency (1.8-fold) in T2D patients requiring ICU admission relative to those treated in general wards (Gen) (Fig.   4B ). The decrease in lymphocyte and monocyte proportions is corroborated by hospital issued We next applied unsupervised analyses to our cytometry data. Consisting of dimensional reduction by the tSNE algorithm (van der Maaten & Hinton, 2008), marker mapping by projecting known lineage markers to the tSNE map and evaluating variation between patients. Visual analysis of tSNE maps confirmed the monocyte and lymphocyte dynamics associated with T2D and with COVID-19 severity; notably a marked loss of CD14+ monocytes and CD8+ lymphocytes in T2D patients with severe COVID-19; versus a specific loss of CD8+ lymphocytes in ND patients with severe COVID-19 ( Fig 4D) . When projecting IRF5 expression over the tSNE maps, we confirm monocyte-specific expression, maintained at a high level despite marked monocytopenia in severe COVID-19 with T2D.

This article is protected by copyright. All rights reserved Discussion 2020 has been marred by the emergence of SARS-CoV-2 affecting over 4.5 million people globally. The resulting Coronavirus Disease (COVID)-19 has placed unprecedented strain on health services and claimed over 300 thousand lives (Dong et al., 2020) . With diabetic patients accounting for approximately 10% of COVID-19 deaths urgent mobilization of diabetologists and diabetes researchers is required to define criteria that confer risk. An example of such valuable work has found that appropriate glycaemic control is a key determinant of survival amongst T2D patients with COVID-19 (Zhu et al., 2020) . Our current study investigates inflammation and immune cell dynamics as possible mechanisms conferring risk of severe COVID-19 in patients with T2D.

In COVID-19 patients with or without T2D, we carried our broad-spectrum immunophenotyping of 15 leukocyte populations and subpopulations in peripheral circulation, evaluating changes associated with diabetic status and disease severity. We found that T2D patients with COVID-19 are characterized by monocytopenia, specific to quiescent monocytes. Monocyte loss was accompanied by morphological alterations and a hyperinflammatory expression profile consistent with the type-1 interferon response. These phenomena, alongside a marked loss of CD8+ T-cells in peripheral circulation characterise severe COVID-19 in pre-existing T2D.

In keeping with recent reports, we confirmed lymphopenia as a hallmark of COVID-19 (Tan et al., 2020) . What we were astounded to observe was the added monocytopenia in patients with T2D. To our knowledge, ours is the first report of monocytopenia specific to T2D patients suffering a coronavirus infection, and such is likely to be a particularity of COVID-19. Monocytopenia has been previously associated with acute infection (Jardine et al, 2019) . Whilst in our current study, duration of COVID-19 was not different between groups and thus monocytopenia is likely specifically related to patient diabetic status. Of note, monocyte loss detected by flow cytometry is corroborated by clinical FBC and thus could serve as an additional COVID-19 screening tool for diabetology practice, with lymphopenia as an established indicator of severity in the general population.

Beyond the quantitative analyses, we identified an exaggerated phenotypic class switch of monocyte subpopulations in COVID-19 patients with T2D. As monocytes undergo activation they transition from their classical phenotype to intermediate and non-classical phenotypes

This article is protected by copyright. All rights reserved gaining expression of CD16 and gradually lowering expression of CD14 (Hijdra et al, 2013) .

We demonstrate an increased rate of transition from the classical phenotype, towards CD16+ intermediate monocytes, and an accelerated loss of CD14 towards the non-classical phenotype in T2D. Both chronic inflammation and viral infection (in particular influenza viruses) are associated with switching monocyte class (Friedrich et al, 2019; Hoeve et al, 2012) . Importantly, monocyte expression of CD16 increases potency of inducing CD4+ T-cell polarisation compared to quiescent (classical) monocytes that are CD16- (Sanchez-Torres et al, 2001) . This could in-part explain the hyperinflammatory response in patients with T2D that have accelerated monocyte activation and a marked loss of quiescent monocytes.

A specific loss of classical monocytes may indeed be due to increased apoptosis when confronted with a viral challenge, as has been reported in in-vitro modelling (Hoeve et al., 2012) .

Alternatively, monocytes in T2D patients may be primed to transition towards their activated damage-seeking state more rapidly than in ND patients. Of note the accumulation of intermediate and non-classical monocytes is associated with increased rate of infection and a largely maladaptive response (Coates et al, 2018; Hoeve et al., 2012; Vangeti et al, 2019) . Moreover, non-classical monocytes have recently been reported to important drivers of pulmonary hypertension in T2D patients . Taken together these data are coherent in explaining, in part, increased risk of severe disease or mortality in COVID-19 patients with T2D.

A recent pre-print reported that monocyte morphological alterations are associated with COVID-19 . These alterations consisted of increased monocyte size (FSC Hi monocytes) in a subset of COVID-19 patients. Interestingly, altered monocyte size has also been reported in infections of influenza virus (Hoeve et al., 2012) . A major novelty of our investigation is the characterisation of these morphologically altered monocytes in T2D. We corroborate the recent pre-print report of FSC Hi monocytes in COVID-19, and we demonstrate an increased frequency of FSC Hi monocytes in T2D. Moreover, we demonstrate that monocyte size is associated with a hyperinflammatory gene expression profile in PBMCs and with admission to ICU of patients with T2D. Surprisingly little is known with regards to the regulation of monocyte morphology, further basic research is required to decipher the natural history and functional implications of such phenomena.

This article is protected by copyright. All rights reserved

With prior knowledge of pathways engaged in both viral and diabetic contexts we targeted a factor that controls transcription of type-1 interferons, IRF5. Previous studies have well-characterised the pro-inflammatory function of IRF5 in tissue macrophages, the progeny of circulating monocytes (Dalmas et al., 2015; Weiss et al., 2015) . In the current study we demonstrate that IRF5 expression in circulating cells is induced in COVID-19 and is increased in activated monocytes of patients with T2D relative to ND patients. Indeed, expression is correlated to that of inflammatory markers. A specific increase in activated subtypes of monocytes is in agreement with previous reports that IFR5 drives monocyte damage-seeking behaviour and differ- in human PBMC and subsequently increased IL8 and IL6 levels in circulation were associated with increased blood glucose in IAV infected patients (Wang et al., 2020a) . The IRF5 expression and cytokine profile reported in IAV infection are similar to what we observe in PBMC from SARS-CoV-2 infected patients, comforting our hypothesis that similar mechanisms are at play. Importantly, the K63-linked ubiquitination of IRF5, required for its nuclear translocation, is an indispensable mechanism in macrophages that mediate metabolic inflammation and loss of glycaemic homeostasis in T2D (independently of viral infection) (Kim et al, 2017) . A recent report has also dissociated IRF5-mediated cytokine production from an inhibitory effect on viral replication in IAV. These studies, and a recent pre-print implicating impaired type-1

This article is protected by copyright. All rights reserved interferon signalling in severity of COVID-19 cases, strongly support a key role for IRF5 and the type-1 interferon response in increased severity in T2D (Forbester et al., 2020; Hadjadj et al, 2020) .

Taken together, our data and previous reports indicate that basal levels of IRF5, preceding-SARS-CoV-2 infection, are dysregulated in T2D patients, our supposition is comforted by a recent opinion article describing the hypothetical molecular mechanisms (Laviada-Molina et al, 2020) . Monocytopenia and rapid class switch of monocytes in T2D with COVID-19, may be the result of an exuberant viral response from an immune system primed on an inflammatory background. IRF5-linked hyperinflammation will induce eager damage-seeking behaviour, antigen presentation and cytokine release, without affecting viral replication. Thus, contributing to the cytokine storm syndrome that characterises severe COVID-19 (Gruber, 2020) .

In our cohort, as in others, not all COVID-19 patients with T2D require intensive care, approximately 10% more T2D patients required admission to ICU than ND patients. The immunophenotype of patients with T2D that required ICU admission was marked by an exacerbated monocytopenia and lymphopenia; in the case of lymphocyte phenotypes we were surprised to find that cytopenia was specific to CD8+ T-cells. A recent correspondence also highlighted a loss of CD8+ cytotoxic lymphocytes (CTLs) in patients with COVID-19, both severe and mild forms (Zheng et al, 2020) . The CTL population is known to play a crucial role in recognising and killing virally infected cells (Koutsakos et al, 2019) . This study by Koutsakos et al demon- strates that CTLs are important in conferring cross-reactivity across a number of viral strains, in effect a key target population that holds important clues for neutralising vaccine development. It is thus not surprising that those patients with under-represented CD8+ T-cells develop a more severe form of disease. A higher frequency of CD8+ T-cells and their efficient interactions with APCs, such as monocytes, may be a key process in mitigating severe disease.

Finally, unsupervised clustering of immune populations based on expression data, also mapped a marked loss CD8+ T-cells to ICU admission of both T2D and ND patients with COVID-19, as well as a loss of monocytes in T2D patients with severe disease. Importantly, when IRF5 is projected onto these clusters, we observe a sustained high level of expression specific to monocytes, even amongst populations that decrease in frequency. These data indicate that in T2D, exuberant inflammation, likely mediated by IRF5 in monocytes, maybe responsible for increased mobilisation of these cells. Their increased mobilisation decreases their abundance in

This article is protected by copyright. All rights reserved peripheral circulation or at sites of interaction with lymphocytic populations. A mismatched ratio of antigen-presenting monocytes to CD8+ T-cells is a tempting mechanism for the descent from mild-moderate COVID-19 to severe-critical COVID-19. Once patients are identified as at-risk at admission, well-timed and -targeted immunosuppressive intervention may prevent the uncontrolled and persistent inflammatory response in severe or mortal COVID-19.

A main limitation of our study is the sample size and diversity, inclusion of veritable mild cases that did not require hospitalisation would help support and extend our conclusions with regards to the factors that increase COVID-19 severity. Increasing sample size and diversity within the T2D group would also allow the further stratification of patients based on severity of diabetes, in terms of glycaemic control or the existence of complications or comorbidities. Although the current study hypothesised that T2D itself was a risk-factor through increasing systemic inflammation, and thus we aimed and achieved the recruitment of groups comparable in terms of age, BMI, gender and disease duration (as well as clinical factors that indicate severity such as CRP, D-dimers). Lastly, the cytokine storm syndrome was not documented in this cohort; however, several publications have very concretely established its presence in COVID-19 cases.

Given the time-sensitive nature of this public health problem we privileged novel analyses to directly address the hypothesis.

All consecutive patients hospitalised in April 2019 for COVID-19 infection in the dedicated University Centre of Diabetes and its Complications, Lariboisière hospital, Paris, France, were prospectively included in the study. Clinical and anthropometric data are summarised in Table   1 . COVID-19 diagnosis was based on positive oropharyngeal swab RT-PCR. Exclusion criteria were type 1 diabetes, immunotherapy for previous transplantation, and treatment of COVID-19 by corticotherapy or immunotherapy before inclusion. For the analysis, patients were divided into two groups: with or without T2D. Patients with T2D are patients already known to have it before hospitalisation or patients for which diabetes has been discovered during hospitalisation (HbA1c > 6. 5% or two fasted glycemia above 7 mmol/l). The study was conducted in accordance with the Helsinki Declaration and was registered in a public trial registry (Clin-

This article is protected by copyright. All rights reserved icaltrials.gov; NCT02671864). This study was approved by local institutions and ethical committees, the Ethics Committee of CPP Ile-de-France granted approval for all individuals (Ile de France V number 15070). Non-COVID-19 T2D patients were included from the same clinical service prior to the COVID-19 pandemic as part of an on-going observational study (NCT02671864), patients were matched to the T2D COVID-19 cohort in terms of age, gender, BMI, hypertension and HbA1c. All patients provided informed consent indicating that they understood the nature of their participation in the study (NCT02671864). The principal investigator of this clinical trial is Prof. Gautier Jean-François: jean-francois.gautier@aphp.fr.

Sampling, clinical data (age, gender, BMI, Diabetes Duration, history of HTA, COVID duration since 1s symptoms) and biological data (HbA1c, CRP, lymphopenia, D-dimer) were collected at inclusion in a standardised manner; events like introduction of COVID-19 specific treatments, transfer in Intensive Care Unit (ICU) and death were collected at the end of the hospitalization. Minimum lymphocyte count and maximal CRP were collected at the end of the hospitalization.

Blood cells were obtained from 1 mL of venous blood, after red blood cell lysis and resuspended into FACS buffer as previously described (Julla et al, 2019) . After 10 min incubation with an Fc blocker (120-000-422; Miltenyi), cells were stained for surface markers with the appropriate antibodies and a Live/Dead viability dye (L34957; Thermo Fisher Scientific) according to manufacturers' protocol. The following antibodies were used: anti-HLA-DR (AC122) and anti-CD8 (BW135/80) from Miltenyi; anti-CD14 (MΦP9), anti-CD3 (UCHT1) and anti-CD123 (7G3) from BD Biosciences; anti-CD16 (3G8), anti-CD56 (HCD56), anti-CD20 (2H7) and anti-CD11c (3.9) from Biolegend; anti-CD4 (S3.5) and anti-CD45 (HI20) from Thermo Fisher Scientific. After washing, cells were fixed and stained using the Foxp3staining kit (00-5523-00; Thermo Fisher Scientific) according to the manufacturer's protocol and using the anti-IRF5 (ab21689; Abcam) antibody for 1h at 4°C in the dark, followed by the donkey-anti-Rabbit-PE (12-4739-81; Thermo Fisher Scientific) secondary antibody for 20 minutes at 4°C in the dark. Antibodies were diluted in the following ratios: 1:200 for anti-HLA-DR, -CD14, -CD45, -CD3, -CD16, -CD20, -CD4, -CD8 and -IRF5; 1:100 for anti-CD56 and -CD123; 1:50 for anti-CD11c and for the secondary PE antibody. Viability dye was diluted

This article is protected by copyright. All rights reserved at 1:1000 following the manufacturer's protocol. Acquisition was performed on a LSR-Fortessa flow cytometer (BD Biosciences) and analysed with FlowJo software (Tree Star). Immune lineage markers and antibodies were chosen based on the Immunological Genome consortium guidelines and gating strategies have been previously published (Autissier et al, 2010; Heng et al, 2008; Melzer et al., 2015) .

RNA was extracted from blood cells (PBMCs) using the RNeasy RNA Mini Kit (Qiagen).

Complementary DNAs were synthesised using super script kit (Promega). RT-qPCR was performed using the QuantStudio 3 Real-Time PCR Systems (ThermoFisher Scientific). 18S was used for normalization to quantify relative mRNA expression levels. Relative changes in mRNA expression were calculated using the comparative cycle method (2 −ΔΔCt ). Primer sequences were designed using Primer3 (Koressaar & Remm, 2007; Untergasser et al, 2012) 

Data are expressed as mean or median ± SD or SEM as indicated in the text, tables and figures.

For quantitative data, differences between groups were evaluated with non-parametric Mann-Whitney U test, and categorical and binary variables were tested by the two-tailed Pearson chisquare test or Fisher exact test if more than 20% of the cells in the frequency tables had an 

This article is protected by copyright. All rights reserved quantification with FactoMineR R package (doi 10.18637/jss.v025.i01), and factoextra package (factoextra.bib) was used to construct graphics. Contribution of each individual was analysed to identify outliers biasing the PCA, leading to exclusion of 4 individuals for a technical bias or hospitalisation in the ICU prior to COVID-19 infection. Given the pressing circumstances during COVID-19 pandemic, a power study was not carried out prior to recruitment, sample size was judged sufficient when differences of immunophenotypic were observed. For detailed sample size and exact p-value per figure panel see Appendix Table S5 .

The computer code and software tools used in this study are available: -R Software 3.6.0 (http://www.r-project.org). R Core Team (2013 

Flow cytometric quantification of lymphocytes, monocytes, B-cells, natural killer (NK) cells, dendritic cells (DCs) and granulocytes in peripheral venous blood samples from non-diabetic (ND) and type-2 diabetic (T2D) patients with COVID-19.

Quantification of monocyte subpopulation phenotypes as classical (CD14 Hi CD16 -), intermediate (CD14 Hi CD16 + ) or non-classical (CD14 Lo CD16 + ).

Principle component analysis of lymphocyte and monocyte population frequencies in ND and T2D COVID-19 patients and in T2D patients without COVID-19.

Data information: Data are presented as mean +/-SEM. Differences between groups were evaluated with unpaired t-test. See also Appendix Figure S1 and Appendix Tables S1-3. Sample size and exact pvalue in Appendix Table S5 . 

Quantification of CD14 expression and size (FSC) in monocyte populations from non diabetic (ND) and type-2 diabetic (T2D) COVID-19 patients.

Frequency of conventional (FSC Lo ) and large (FSC Hi ) monocytes in ND and T2D COVID-19 patients.

Expression of CD16, CD14 and HLA-DR in FSC Lo and FSC Hi monocytes from COVID-19 patients.

Proportions of classical, intermediate and non-classical monocytes within FSC Lo and FSC Hi monocytes from COVID-19 patients.

Correlative analyses of IL8 expression in peripheral blood mononuclear cells (PBMCs) to monocyte FSC.

IL8, IL6 and CCL2 mRNA expression in PBMCs from ND and T2D COVID-19 patients.

G Monocyte size quantified in ND and T2D COVID-19 patients treated in general wards (Gen) or in intensive care unit (ICU).

Data information: Data are presented as mean +/-SEM. Differences between groups were evaluated with unpaired t-test (except for c. and d. where paired by patient). Analyses of variance (ANOVA) or covariance (ANCOVA) were used for multiple group comparisons. For correlatiive analysis Spearman's test was carried out calculating a 2-tailed p-value. See also Appendix Figure S2 . Sample size and exact p-value in Appendix Table S5 . Quantification of IRF5 and IFNB1 mRNA expression in peripheral blood mononuclear cells of non-diabetic (ND) and type 2 diabetic (T2D) COVID-19 patients (A).

Histograms of IRF5 expression on different populations analysed by flow cytometry on venous blood samples.

This article is protected by copyright. All rights reserved C IRF5 median fluorescence intensity (MFI) in monocytes of ND and T2D patients with COVID-19.

IRF5 expression overlaid onto monocyte phenotypic gating. E IRF5 expression (MFI) in monocyte subtypes from ND and T2D COVID-19 patients.

F HLA-DR and IRF5 expression in monocytes from COVID-19 patients.

G IRF5 expression in monocytes of ND or T2D COVID-19 patients admitted to intensive care unit (ICU) or treated exclusively in general wards (Gen) .

IRF5 expression in monocytes of ND or T2D COVID-19 patients admitted ICU or treated exclusively in Gen.

Data information: Data are presented as mean +/-SEM. Differences between groups were evaluated with unpaired t-test. Analyses of variance (ANOVA) was used for multiple group comparisons. For correlative analysis Spearman's test was carried out calculating a 2-tailed p-value. See also Appendix Figure S3 . Sample size and exact p-value in Appendix Table S5 . 

Pie charts of COVID-19 hospitalisation that were exclusively treated in general wards (Gen) or that required intensive care (ICU). Proportions of patients admitted to ICU that were non-diabetic (ND) or with type-2 diabetes (T2D).

Proportions of lymphocytes and monocytes in peripheral venous blood from T2D patients with COVID-19 either treated in Gen or requiring ICU admission.

Phenotypic analysis of lymphocyte and monocyte subpopulations in peripheral venous blood from T2D COVID-19 patients treated in Gen or requiring ICU treatment.

tSNE mapping of all cytometric acquired data with projections of population density, CD8 or IRF5 IRF5 expression. Maps are of representative profiles from each group.

Data information: Data are presented as mean +/-SEM. Differences between groups were evaluated with unpaired t-test or non-parametric Mann-Whitney U test. See also Appendix Figure S4 . Sample size and exact p-value in Appendix Table S5 .

Immunophenotyping of lymphocyte, monocyte and dendritic cell subsets in normal rhesus macaques by 12-color flow cytometry: clarification on DC heterogeneity

Inflammatory Monocytes Drive Influenza A Virus-Mediated Lung Injury in Juvenile Mice

IRF5 promotes intestinal inflammation by guiding monocyte differentiation towards a pathogenic CD11c+ macrophage phenotype

Irf5 deficiency in macrophages promotes beneficial adipose tissue expansion and insulin sensitivity during obesity

An interactive web-based dashboard to track COVID-19 in real time

IRF5 Promotes Influenza Virus-Induced Inflammatory Responses in Human Induced Pluripotent Stem Cell-Derived Myeloid Cells and Murine Models

Perturbation of the Monocyte Compartment in Human Obesity

Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

The Immunological Genome Project: networks of gene expression in immune cells

Phenotypic characterization of human intermediate monocytes

Influenza virus A infection of human monocyte and macrophage subpopulations reveals increased susceptibility associated with cell differentiation

Lipopolysaccharide inhalation recruits monocytes and dendritic cell subsets to the alveolar airspace

Isolation and Analysis of Human Monocytes and Adipose Tissue Macrophages

Cytosolic Pellino-1-Mediated K63-Linked Ubiquitination of IRF5 in M1 Macrophages Regulates Glucose Intolerance in Obesity

Enhancements and modifications of primer design program Primer3

Human CD8(+) T cell cross-reactivity across influenza A, B and C viruses

Working Hypothesis for Glucose Metabolism and SARS-CoV-2 Replication: Interplay Between the Hexosamine Pathway and Interferon RF5 Triggering Hyperinflammation. Role of BCG Vaccine?

Reference intervals for leukocyte subsets in adults: Results from a population-based study using 10-color flow cytometry

Leukocyte profiles differ between type 1 and type 2 diabetes and are associated with metabolic phenotypes: results from the German Diabetes Study (GDS)

CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography

CD16+ and CD16-human blood monocyte subsets differentiate in vitro to dendritic cells with different abilities to stimulate CD4+ T cells

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Visualizing Data Using t-SNE

Human Blood and Tonsil Plasmacytoid Dendritic Cells Display Similar Gene Expression Profiles but Exhibit Differential Type I IFN Responses to Influenza A Virus Infection

O-GlcNAc transferase promotes influenza A virus-induced cytokine storm by targeting interferon regulatory factor-5

Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients

IRF5 controls both acute and chronic inflammation

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Nonclassical Monocytes Sense Hypoxia, Regulate Pulmonary Vascular Remodeling, and Promote Pulmonary Hypertension

COVID-19 infection induces readily detectable morphological and inflammation-related phenotypic changes in peripheral blood monocytes, the severity of which correlate with patient outcome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes

ASSERADT (a non-profit patient association). E.D was supported by grants from the French and European Foundation for Diabetes (SFD and EFSD). We would like to thank Hélène Fohrer-Ting of the Centre for Cytometry, Histology and Cellular Imaging (CHIC) core facility of

This article is protected by copyright. All rights reserved The Paper Explained PROBLEM COVID-19 severity is associated with progressive lymphocytopenia and systemic inflammation. Type 2 diabetes (T2D) is characterised by chronic low-grade inflammation and is a riskfactor for severe COVID-19. Is COVID-19 severity in T2D associated with distinct inflammatory and immunophenotypic variations? RESULTS COVID-19 and its severity with pre-existing T2D are associated with monocytopenia and altered morphology. Interferon-driven inflammation and monocyte phenotypes are also perturbed in COVID-19 with T2D. Severe COVID-19 is associated with lymphocytopenia of CD8+ cells in the general population, while monocytopenia of classical monocytes is a specific to patients with T2D IMPACT Monocyte frequency and morphology are fast and reliable metrics to assess COVID-19 severity in patients with T2D. The inflammatory profile we observed supports the therapeutic application of anti-inflammatory drugs.

This article is protected by copyright. All rights reserved Figures   Table 1 

Age ( 

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved

This article is protected by copyright. All rights reserved